Understanding how azithromycin affects antibiotic resistance in children in Niger.
Résistance Evaluée contre la Vie des Enfants au Niger-Implementation et Recherche (REVENIR). Community antimicrobial resistance after azithromycin distribution: selection, spillover, co-selection
This study is looking at how giving a common antibiotic called azithromycin to young children in Niger affects the development of antibiotic resistance, helping us understand if this treatment could lead to problems with other antibiotics in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10995344 on NIH RePORTER |
What this research studies
This research investigates the effects of mass distribution of azithromycin on antibiotic resistance in children aged 1 to 59 months in Niger. It aims to understand how this treatment impacts the emergence of antimicrobial resistance (AMR) over time and whether resistance spreads from treated to untreated populations. The study will analyze patterns of AMR and explore the potential for co-selection of resistance to other antibiotics. By examining these factors, the research seeks to inform future public health strategies regarding azithromycin use in child health programs.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 1 to 59 months who are receiving azithromycin as part of a mass drug administration program.
Not a fit: Patients who are older than 59 months or those who are not part of the azithromycin distribution program may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help optimize the use of azithromycin in child health programs while minimizing the risk of developing antibiotic resistance.
How similar studies have performed: Previous studies have shown mixed results regarding the impact of azithromycin on antibiotic resistance, indicating that this research is addressing important unanswered questions.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: O'brien, Kieran — University of California, San Francisco
- Study coordinator: O'brien, Kieran
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.